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ABSTRACT 
In recent times, a great deal of interest has been motivated on plant derived compounds known as nutraceuticals. 
These compounds exert important beneficial activities that improve people’s health status when are consumed 
regularly, and now they appear as a viable option to explore their possible therapeutic effects against diseases 
like cancer. Particularly, lupane-type triterpenes have shown great ability to modulate multiple cancer-related 
signaling pathways and processes, including NF-κB, Wnt/β-catenin, PI3K/Akt, apoptosis, and many other routes 
related to proliferation or cell death, which are uncontrolled in malignant tumors. These investigations have 
promoted in vitro and in vivo studies, searching their mechanisms of action; although more research is still need-
ed to prove its potential in human clinical trials. This review focuses on the ability of betulin, betulinic acid and 
lupeol to show benefits against the most common types of malignant tumors, which are considered a major glob-
al threat for public health. 
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INTRODUCTION 
In present times, non-communicable 
chronic diseases are responsible for about 
63 % of deaths worldwide. This group in-
cludes diabetes mellitus (DM), cardiovascu-
lar diseases (CVD), chronic respiratory dis-
eases (CRD) and cancer, being responsible 
for approximately 38 million of deaths per 
year; 75 % of these deaths (28 million) occur 
commonly in third world countries. 
Cancer is a generic term that comprises a 
large number of diseases that affect distinct 
parts of the human body. It is characterised 
by uncontrolled cell growth, and is capable 
to disseminate to different tissues from 
where it was originated (metastasis), leading 
to people´s death. Cancer is responsible for 
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one in every seven deaths worldwide (14.1 
million of cancer’s new cases are detected 
that causes 8.2 millions of deaths per year), 
causing even more deaths than the acquired 
immunodeficiency syndrome (AIDS), tuber-
culosis and malaria combined, making it a 
serious public health problem. Malignant 
tumors are the second leading cause of death 
in high-income countries (5.3 million of de-
ceases) after CVD, and third cause in mid-
dle-low income countries (2.9 million of 
deaths) after CVD and parasitic-infectious 
diseases (American Cancer Society, 2015a). 
Principal cancer types that caused more 
deaths in 2012 were lung (1.59 millions), 
liver (745,000), gastric (723,000), colorectal 
(694,000), and breast cancer (521,000) 
(Stewart and Wild, 2014). 
Cancer’s chemoprevention has become 
increasingly important in modern times, and 
implies the use of natural, synthetic or bio-
logical agents to reverse, suppress or prevent 
early stages of carcinogenesis, as well as the 
progression of pre-malignant cells to an in-
vasive disease (Sporn, 1976). Even though 
there are many treatments to different cancer 
types (i.e. surgery, chemotherapy, radiation 
therapy, targeted therapy and immunothera-
py), these treatments have shown many col-
lateral effects on patients. A balanced cancer 
inhibition involves prevention, early diagno-
sis, effective treatment, and includes pallia-
tive therapy.  
Nowadays, it is known that plants pro-
duce a wide range of phytochemicals (non-
nutritional compounds, i.e. secondary me-
tabolites) and some of such compounds are 
credited as health promoters. It is also im-
portant to note that people are more con-
cerned on taking care of their diet, having a 
higher intake of plant-derived products. 
These products might contain phytochemi-
cals that could exert biological activities 
against chronic-degenerative diseases such 
as cancer, thus contributing to improve 
health status of people. These biological ac-
tivities are explained by the presence of 
nutraceuticals. This term was used the first 
time in 1989 by Dr. Stephen DeFelice com-
bining the terms “Nutrition” and “Pharma-
ceutical”.  Most of nutraceuticals are safer, 
less toxic and with less side effects com-
pared to synthetic drugs (McAlindon, 2006). 
Some nutraceuticals show chemopreventive 
activities, inhibiting or interfering with the 
process of disease (Surh, 2003); among 
nutraceuticals phytosterols seem to be a 
promising group of bioactive compounds.  
Phytosterols include plant sterols and 
stanols. They are natural occurring com-
pounds that can be found in many plants de-
rived foods and food supplements, mainly 
those rich in oil content or products derived 
therefrom. Average intake of these com-
pounds in normal diets ranges between 178 
to 463 mg per day (Andersson et al., 2004).  
Terpenes are members of the phytosterol 
family, and can be found in a wide variety of 
living organisms like prokaryotic cells as 
well in eukaryotic organisms (plants and an-
imals). However, composition of plants has 
shown to be richer on these compounds with 
biological activity than any other organisms. 
These compounds are derived from isoprene 
units (C5H8), and are classified according to 
their number of carbons, thus they are named 
such as mono-(C10), sesqui-(C15), di-(C20), 
sester-(C25), tri-(C30) and tetra-(C40) ter-
penes. Isoprene units can be acyclic or poly-
cyclic (mono, bi, tri, tetra or penta). Accord-
ing to their complexity these compounds can 
be found in different parts of plants, simple 
terpenes (mono or sesquiterpenes) are found 
in essential oils of plant raw materials, while 
more complex terpenes (i.e., triterpenes) are 
found in resins and balms (Muffler et al., 
2011).  
A group of terpenes with particular im-
portance are triterpenes; about 30,000 differ-
ent triterpenes have been identified and clas-
sified according to their structures and chem-
ical properties, and can be found in the form 
of aglycones or as free acids. The most 
common triterpene structures include penta-
cyclic (taraxanes, oleananes, ursanes, lu-
panes and baccharanes) and tetracyclic 
(dammarane, curcubitane and euphanes), be-
ing oleananes and ursanes the most abundant 
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in higher plants (Dzubak et al., 2006; Naza-
ruk and Borzym-Kluczyk, 2015; Yin, 2015). 
Emphasizing from biological perspective, 
the most important triterpenes are the penta-
cyclic oleanane, ursane, lupane (Figure 1), 
and the tetracyclic dammarane, euphane 
structures (Muffler et al., 2011).  
 
Figure 1: Principal pentacyclic triterpenes struc-
tures. 
Triterpenes are often recognized as bio-
active compounds, and are subjected to mul-
tiple phytochemical and pharmacological 
studies. Several research studies have been 
conducted in recent times in order to eluci-
date the mechanisms and modulatory activity 
in different signaling pathways, by which 
these compounds exhibit benefits against dif-
ferent cancer types. This review focuses on 
natural triterpenes especially the lupane-type 
triterpenes betulin, betulinic acid and lupeol 
(Figure 2), and their activities against the 
most common cancer types among men and 
women, highlighting the benefits of these 
compounds in prevention and treatment of 
malignant tumors. 
 
 
Figure 2: Chemical structures of principal lu-
pane-type triterpenes 
Lupane 
Oleanane 
Ursane 
Betulin 
Betulinic acid 
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SIGNALING PATHWAYS INVOLVED 
IN CANCER 
Cancer is characterized by an abnormal 
cell growth due to aberrant gene expression 
patterns. Most of cancers are acquired by al-
teration of genetic codes (caused by the ac-
cumulation of mutations in somatic cells). 
Normal cells have very strict regulatory 
mechanisms between cell growth, division 
and apoptosis, maintaining a homeostatic 
state. Cancer cells show independence from 
this growth signals, due to specific mutations 
on particular genes that control proteins in-
volved on intracellular signaling pathways. 
Growth signals independence shown by can-
cer cells allow them to enter on the cell cycle 
regardless of external stimuli (Foster, 2008). 
The enormous genomic instability within 
cancer cells, leads to immortality and fast 
cell and tissue transformation (Artandi and 
DePinho, 2009). Generally, principal genes 
affected in cancer can be divided into two 
groups: oncogenes and tumor suppressor 
genes. Oncogenes (which are phenotypically 
dominant, i.e., only one mutation in an allele 
is enough to cancer promotion) regularly suf-
fer gain function mutations, like gene ampli-
fication (overexpression) or production of 
mutant proteins with unusual activity, favor-
ing growth, division and enhanced survival 
of cancer cells. On the other hand, tumor 
suppressor genes (which are phenotypically 
recessive, i.e., it is necessary a function loss 
of the two alleles towards cancer promotion) 
have the function to inhibit cell proliferation 
and survival. Tumor suppressor genes are of-
ten related to control cell cycle progression 
and apoptosis, because these genes are re-
sponsible for preventing uncontrolled cell 
growth, DNA repair, and also are responsible 
for regulation of multiple cell cycle control 
checkpoints (Doucas and Berry, 2006; Wein-
stein et al., 2008; Zhang et al., 2007). 
Some examples of proteins (oncogene 
mutation) most commonly mutated in cancer 
are: non-receptor tyrosine kinases (nRTKs; 
e.g. Src), receptor tyrosine kinases (RTK; 
e.g. EGFR, ErbB), serine/threonine kinases 
(e.g. Akt), transcription factors (e.g. NF-κB, 
Myc), small GTPases (e.g. Ras), lipid kinas-
es (e.g. PI3K) and nuclear receptors (e.g. 
ER), cell cycle regulators (e.g. cyclins), and 
proliferative pathways (e.g. Wnt). Deletions 
lead to inactivation of tumor suppression 
proteins, such as PTEN (antagonist of the 
PI3K/Akt pathway), retinoblastoma protein 
(pRb), cyclin-dependent kinase inhibitors 
(CKI), p53, etc. Protein p53 is probably the 
most studied in cancer research and is known 
as the guardian of genome. Protein p53 is ac-
tivated when some damage is detected on 
DNA, triggering apoptotic signals and stop-
ping cell cycle progression, hence it has high 
relevance in studies of anticancer activities 
(Lee and Muller, 2010; Sever and Brugge, 
2015; Weinberg, 2013). 
 
ANTI-CANCER ACTIVITIES OF  
LUPANE-TYPE TRITERPENES 
Lung cancer 
Lung cancer possesses the highest preva-
lence and mortality worldwide, its life ex-
pectancy for over five years is fateful (only 
16 %); even with chemotherapy less than 
20 % of patients live more than five years 
(Keith and Miller, 2013). Combined with 
these dismal numbers, advances in lung can-
cer treatment still remain poor compared to 
other types of malignant tumors such as 
breast, prostate and colon, because surgery 
results unfeasible. In this sense, many re-
searches have been conducted in order to de-
termine whether lupane-type triterpenes ex-
hibit some benefit on this type of malignant 
tumor. Cancer is consequence of many ge-
netic changes where normal cells become 
malignant, being the disruption of programed 
cell death one of the main mechanisms of 
cancer (Hanahan and Weinberg, 2000). 
Apoptosis has been linked long time ago 
with the elimination of cancer cells and tu-
mor progression (Kerr et al., 1972). Betulin 
has shown to induce apoptosis on lung cell 
line A549, when apoptosis induction was in-
creased by 27 % compared with untreated 
control, showing an IC50 (20 µM) almost 
equal to cisplatin (25 µM) (Pyo et al., 2009). 
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Cisplatin is well known as an apoptosis in-
ductor (Barry et al., 1990), however betulin 
has not toxic effects even at high doses 
(Makarova et al., 2011), which is an ad-
vantage compared to cisplatin, because the 
latter causes nephrotoxicity and is the main 
restriction for its dosing (Miller et al., 2010). 
Similar results for apoptosis induction using 
betulin were found by Rzeski et al. (2009) 
against the A549 cell line. Apoptotic effects 
of betulin could be promoted by the apopto-
sis intrinsic pathway (Li et al., 2010). Some 
other activities against lung cancer have been 
shown by betulin. Betulin is capable of in-
creasing expression levels of p21 and p27, 
and reducing levels of Cyclin B, Cyclin D1, 
and Cyclin E, thus it inhibits cell prolifera-
tion through regulation of these checkpoint 
proteins of the cell cycle. Inhibition of cell 
cycle progression is also another important 
mechanism on cancer research. Cell cycle is 
a highly-regulated process by the activation 
of Cdk/cyclin complexes. The p21 and p27 
proteins are family members of Cip/Kip and 
their principal function is the inhibition of 
kinase activity of Cdk/cyclin complexes in 
G1/S and G2/M phases, then regulation of 
both proteins is altered in cancer (Mitrea et 
al., 2012). AMPK is also activated by betulin 
with a decreased phosphorylation of mTOR 
and S6 kinase (Li et al., 2014). AMPK is a 
highly-conserved pathway; in situations 
when nutrients are scare, AMPK regulates 
cell growth mainly by suppressing the 
mTORC1 pathway (by direct phosphoryla-
tion of tumor suppressor TSC2 or RAPTOR) 
(Mihaylova and Shaw, 2011). Betulinic acid 
presents cytotoxic effects against A549 and 
H1650 lung cancer cell lines, because it 
shows IC50 values of 8.92±1.68 and 
7.25±1.54 µg/mL, respectively. Betulinic ac-
id shows also in vivo activities on tumor re-
duction and increased expression of p38, p-
JNK and Bax, and reduction of the anti-
apoptotic marker Bcl-2. Expression levels of 
pro-apoptotic markers such as cleaved caspa-
se-3 and cleaved caspase-8 were significant-
ly increased (Godugu et al., 2014), so this 
activity from betulinic acid can be beneficial, 
because cancer cells usually do not exhibit 
apoptosis as do normal cells. Betulinic acid 
shows effects against lung cancer growth by 
regulation of specificity protein 1 (Sp1) and 
triggering apoptosis (Hsu et al., 2012). Tran-
scription factor Sp1 regulates genes involved 
in cell proliferation like cyclin D1, c-Jun, 
and c-Myc (Wierstra, 2008). Another study 
suggests that growth inhibition of malignant 
lung tumors by betulinic acid are through 
Sp1 degradation (Hsu et al., 2015a). Penta-
cyclic triterpene lupeol has also been report-
ed with anti-cancer activities against lung 
cancer. Lupeol has shown downregulation on 
COX-2 on A549 cell line (Sankaranarayanan 
et al., 2013). COX-2 is a well-known marker 
of cancer; its overexpression has been found 
in lung tumors, being related to a poor prog-
nosis. COX-2 participates in different steps 
of cancer like increasing cell proliferation, 
affecting apoptosis, and thus influencing an-
ti-cancer drugs effectiveness (Sobolewski et 
al., 2010). The 3β-O-succinyl-lupeol (LD9-
4), a derivative from lupeol, has shown to 
induce autophagy via downregulation of the 
mTOR pathway and upregulation of Beclin 1 
(Hao et al., 2011). Autophagy is an im-
portant homeostatic cell process that controls 
the catabolism of proteins and organelles, 
which are processed in autophagosomes, di-
gested in lysosomes, and recycled to main-
tain cellular homeostasis. Autophagy acts as 
a tumor suppressor, which is its role in can-
cer, by preventing the accumulation of dam-
aged proteins and cell organelles (Yang et 
al., 2011).  
 
Hepatic cancer 
Hepatic cancer has two principal types: 
intrahepatic bile duct cancer (ICC) and hepa-
tocellular carcinoma (HCC). Worldwide liv-
er cancer possesses high incidence; hepato-
cellular carcinoma is by itself the sixth most 
common cancer and is the third leading 
cause of cancer-related deaths (Forner et al., 
2012). Liver cancer is twice common in men 
than in women, and its five-years survival 
rate ranges 10-20 %, being one of the poor-
est prognoses among cancers (American 
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Cancer Society, 2015a). The HCC is the 
most common liver cancer type, and is asso-
ciated in many cases with the hepatitis virus 
or cirrhosis. HCC is a disease with important 
regional differences, and its causes may vary 
significantly by region. In Eastern Asia and 
sub-Saharan Africa countries, about 80 % of 
the incidence of HCC is related to hepatitis B 
virus (HBV) as well as exposure to aflatoxin 
B1. Otherwise, in Europe, North America 
and Japan, the main risk factors are high al-
cohol consumption (~40-60 g/day increases 
the risk about 1.5-2.0 times to develop 
HCC), and the hepatitis C virus (HCV) (~15-
20 times prone to develop the disease) (Do-
nato et al., 2002; El-Serag, 2011; Forner et 
al., 2012).  
Some biological activities of lupane-type 
triterpenes have been investigated. Results of 
these scientific investigations found that they 
are able to show benefits against risk factors 
that trigger liver cancer. Lupeol has hepatic-
protective activities against aflatoxin-B1 in-
duced liver damage, restoring activity levels 
of hepatic enzymes LDH, AST, ALT, ALP 
and reducing oxidative stress trough gluta-
thione and antioxidant enzymes, normalizing 
their levels, and counterbalancing depletion 
of the antioxidant systems (Preetha et al., 
2006). Oxidative stress is an imbalance in 
reactive oxygen species (ROS) production, 
and the capacity of endogenous antioxidant 
system (SOD, CAT, and glutathione system) 
to control its concentration in the body, less 
than 5 % are toxic to the body if they in-
crease their concentration in the organism 
(Sosa et al., 2013). If ROS are produced by 
prolonged time period, they can alter bio-
molecules such as proteins, lipids and DNA. 
These DNA alterations can be turned into 
mutations leading to genomic instability, cell 
proliferation and possible neoplastic trans-
formation (Fang et al., 2009; Visconti and 
Grieco, 2009). Ethanol consumption is also 
anther risk factor for hepatic cancer devel-
opment. Ethanol produces liver fibrosis; in 
this sense betulin and betulinic acid are ca-
pable of downregulating CYP2E1 activity, 
this enzyme plays a crucial role on ethanol-
induced fatty liver and in alcohol detoxifica-
tion. Alcohol toxicity is decreased when 
CYP2E1 is inhibited (Lu and Cederbaum, 
2008). Betulinic acid is also capable of pre-
venting hepatic alcoholic damage by improv-
ing the antioxidant system (increasing the ac-
tivity of SOD, CAT, GPx and reducing the 
levels of malondialdehyde in mice treated 
with betulinic acid) (Yi et al., 2014). Alco-
hol-induced liver damage with ethanol was 
attenuated by betulin and betulinic acid by 
downregulating ROS production, preventing 
NF-κB and JNK phosphorylations, and play-
ing a crucial role on inflammation prevention 
(Szuster-Ciesielska et al., 2011). Betulinic 
acid also exhibits beneficial activities against 
HCV by downregulation of COX-2 expres-
sion at transcriptional level by preventing 
NF-κB phosphorylation and later DNA bind-
ing (Lin et al., 2015). Nowadays, it is well 
known that high abnormal activities of in-
flammatory transcription factors (i.e. NF-κB, 
JNK) and cytokines can be related to cancer 
development (Mantovani et al., 2008). In this 
sense, lupane-type triterpenes offer remarka-
ble beneficial effects on liver cancer-related 
risk factors.  
The observed beneficial effects of lu-
pane-type triterpenes on hepatic cancer high-
lights the great potential of this type of com-
pounds for the prevention and possible 
treatment of this disease. Anti-cancer activity 
of triterpenes extracts (with principal com-
ponents such as betulin, lupeol and betulinic 
acid) against HCC cells derived from a xeno-
graft model was achieved due to an increase 
in caspase 3/7. This extract had less cytotox-
ic activity on healthy hepatocytes, and re-
quired eight times more concentration to 
cause some disturbance on cell viability. 
This anti-hepatocellular carcinoma activity 
from triterpene extracts was through the in-
trinsic apoptosis pathway (Hertrampf et al., 
2012). Undoubtedly, triterpenes show the 
advantage of non-toxic effects on healthy 
cells and being selective against cancer cells 
(Zuco et al., 2002). Betulinic acid is capable 
of apoptosis induction in hepatoblastoma 
cells through PI3K/Akt growth inhibition 
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and caspase 3 activation (Eichenmüller et al., 
2009). Lupeol suppresses tumorigenesis in 
HCC cells by reducing CD133 and modula-
tion of PTEN–Akt pathway (Lee et al., 
2010). The potential against liver cancer of 
betulinic acid could be related to its anti-
tumor activity and apoptosis induction by 
p53-regulated p66shc (Yang et al., 2015). The 
PI3K/Akt pathway is one of the main cell 
survival pathways. It is activated by different 
types of cellular stimuli (but also activated 
by toxic agents) and regulates fundamental 
cellular functions such as proliferation, 
growth, transcription, cell cycle and apopto-
sis (Cantley, 2002; Vanhaesebroeck and 
Alessi, 2000). All these regulatory activities 
shown by lupane-type triterpenes give them 
a promising future in research and develop-
ment of new therapeutic agents for the treat-
ment of liver cancer. 
 
Gastric cancer 
Gastric cancer is the fifth most common 
cancer and remains as one of the leading 
cancer-related deaths around the world (Fer-
lay et al., 2014). Stomach cancer is only ex-
ceeded by lung and liver cancers in death in-
cidences. Gastric cancer is quite common in 
countries like Japan, China, Korea, Russia 
and regions such as Central and South Amer-
ica (Torre et al., 2015). Principal stomach 
cancer type is adenocarcinoma with about 
90 % of the incidences, other gastric malig-
nant tumors types occur as lymphomas and 
sarcomas, etc. (Karimi et al., 2014). Many 
risk factors have been associated to gastric 
cancer development like smoking tobacco, 
dietary patterns, poor vegetables and fruits 
intake, uncontrolled consumption of non-
steroidal anti-inflammatory drugs (NSAIDs), 
obesity and Helicobacter pylori chronic in-
fection with about 75-89 % of cases in this 
type of cancer (Plummer et al., 2014). Gas-
tric cancer still has poor prognosis, its five- 
year life expectancy rate is about 20 % 
(Karimi et al., 2014). 
Typical gastric cancer treatment includes 
surgery, which is undoubtedly the only po-
tentially curative treatment for stomach can-
cer. An increase on patients’ survival rates 
has been observed by combining treatments 
such as chemotherapy or radiotherapy with 
surgery (Orditura et al., 2014). However, 
chemotherapeutical drugs always carry side 
effects. In this sense, research with lupane-
type triterpenoids has found interesting bio-
logical activities against this pathology, 
without the undesirable side effects caused 
by chemotherapy or could help to enhance 
the effects of the chemotherapeutical drugs. 
Betulin dinicotinate has shown protective ef-
fects against indomethacin and ethanol gas-
tric induced-ulcers (Flekhter et al., 2002). 
Lupeol also possesses protective properties 
on ethanol-induced gastric damage (Lira et 
al., 2009). It is well known that ulcers can be 
related to stomach cancer development, thus 
betulin and lupeol could act as good preven-
tive agents. Betulin and related compounds 
have shown interesting protective activities. 
Betulinic acid is capable to exhibit a better 
cytotoxic effect than betulin against human 
gastric drug-resistant cell lines 257P, 
257RNOV, and 257RDB, being the IC50 for 
betulin in the range of 10.97-18.74 µM and 
for betulinic acid 2.01-6.16 µM (Drag et al., 
2009). Cytotoxic effects from betulin and 
betulinic acid extracted from Belamcanda 
chinensis against human gastric cancer cell 
line MGC-803 have been reported (Liu et al., 
2012). Betulin can induce intrinsic apoptosis 
pathway on SGC7901 human gastric cancer 
cell line through caspase 3/9 upregulation, 
and intracellular ROS played a crucial role in 
this apoptosis induction process (Li et al., 
2016). Betulinic acid induces apoptosis on 
human gastric adenocarcinoma (AGS) cell 
line, through cell cycle arrest on G2/M 
phase; cyclin B2 expression was down-
regulated by the betulinic acid treatment 
(Yang et al., 2010). Cell cycle regulation is 
always important for cancer treatment, main-
ly because cancer cells are incapable for reg-
ulating its own growth. Cyclin B1/CDK1 
complex has a crucial role in cell cycle pro-
gression; it is the checkpoint to G2/M phase 
transition and subsequent onset of mitosis 
(Pines and Hunter, 1990). The ability of lu-
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pane-type triterpenes in apoptosis and cell 
cycle regulation is highly important in the 
quest for new therapeutic agents for treat-
ment of cancer. Recent approaches have 
found that lupeol possesses anti-gastric can-
cer activities. Lupeol is capable of enhancing 
the cytotoxic function of natural killer (NK) 
cells against gastric cancer cells (Wu et al., 
2013). This result is very important due to 
NK cells playing an important role in tumor 
development, and many models have shown 
that deficiency on these immune cells causes 
more aggressive tumors (Waldhauer and 
Steinle, 2008).  
Furthermore, a recent research suggests 
that lupane-type triterpene lupeol displays a 
chemo-sensitization and enhancement of the 
inhibitory effect shown by 5-fluorouracil (5-
FU) in gastric cancer, inducing apoptosis by 
upregulation of Bax (pro-apoptotic protein) 
and p53, and downregulation of survivin and 
Bcl-2 (anti-apoptotic protein) (Liu et al., 
2016). All these results taken together sug-
gest a great anti-gastric cancer potential by 
such compounds, and could act as potential 
candidates for stomach cancer treatments, 
always with the awareness that lupane-type 
triterpenes are not substitutes to current 
treatments. 
 
Colorectal cancer 
Colorectal cancer (CRC) is the third most 
common malignant tumor type (1.4 million 
new cases per year are reported), and is the 
fourth leading cause of cancer-related deaths 
worldwide, causing approximately 694,000 
(~8 % of total cancer-related deaths) mortali-
ties annually (Ferlay et al., 2014). This dis-
ease is related to age, and is principally di-
agnosed on mature adults (~50 years old), 
while in young people it is quite rare. Aver-
age age for diagnosis is around 66 years for 
males and 70 years for females (Miller et al., 
2016). Colorectal cancer has important geo-
graphical differences, because it is more 
common in developed countries with a west-
ern lifestyle like Europe, North America, and 
Australia; and lower risk incidence is found 
in countries of Africa, South America and 
Asia (Center et al., 2009; Haggar and 
Boushey, 2009). Colorectal cancer unlike the 
other cancer types commented above in this 
review does not have a dismal prognosis; its 
five-year survival rate is about 65 % and the 
rate for 10-year survival is 58 % (Miller et 
al., 2016), these are encouraging numbers for 
such a serious condition as this cancer is rec-
ognized. Principal risk factors associated to 
colorectal cancer development includes age 
and inflammatory bowel disease (IBD); 
these risk factors increase 4-20 times the 
possibility for colorectal cancer development 
more than in healthy people (Janout and Kol-
larova, 2001), although family history, ge-
netic factors, nutritional habits, alcohol con-
sumption, obesity and smoking are also im-
portant risk factors (Haggar and Boushey, 
2009). Like in any other cancer type, CRC 
treatment has different procedures: surgery, 
chemotherapy (5-FU, oxaliplatin), radiother-
apy and targeted therapies (bevacizumab, ce-
tuximab), being surgery treatment the most 
used (in early stages 0 and I, surgery may be 
used without any other type of complemen-
tary therapy) (American Cancer Society, 
2014; Hagan et al., 2013). It is remarkable, 
that lupane-type triterpenes have shown in-
teresting effects against CRC, which will be 
mentioned below and their multiple effects 
makes them promising in the treatment of 
this disease. Betulinic acid has been capable 
of preventing the NF-κB activation and its 
nucleus translocation, preventing cell prolif-
eration and activating extrinsic apoptosis 
pathway (TNF-α dependent apoptosis) 
(Takada and Aggarwal, 2003). Betulinic acid 
also showed specific apoptosis induction by 
caspase 3/7 upregulation, and cytotoxic ac-
tivity against colon cancer cell line (HCT 
116), with a minimum cytotoxic effect on 
normal colonic cells (CCD-18Co) (Aisha et 
al., 2012). The preference shown by lupane-
type triterpenes for cancer lines, makes them 
ideal for cancer treatment, because they only 
exhibit their effects on malignant cells. Anti-
CRC effects of betulinic acid have also been 
proven in vivo. Betulinic acid inhibited tu-
mor growth possibly by downregulating 
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VEGF (vascular endothelial growth factor) 
expression at transcriptional level in a xeno-
graft model (Ren et al., 2010). VEGF is 
known to regulate angiogenesis and vascular 
permeability; angiogenesis is an important 
process in tumor growth and development 
(Goel and Mercurio, 2013), because new 
blood vessels feed the tumor with oxygen 
and nutrients, allowing tumor development. 
Betulinic acid has interesting effects on 
drug-resistant CRC cells, compared to other 
standard drugs in CRC therapy such as 5-FU, 
IRT, and OXT; its mechanism of action sug-
gests that betulinic acid triggers apoptosis 
since the levels of cleaved caspase 3 are in-
creased (Jung et al., 2007). Autophagy is an-
other process that is induced by an analogue 
of betulinic acid on HT-29 cells by increas-
ing the level of Beclin 1 (autophagy-related 
protein) and decreasing levels of p62 (Dutta 
et al., 2016). Cell autophagy is a process in 
which stressed cells undergo to lysosomal 
degradation of defective organelles and dam-
aged proteins (Levine and Klionsky, 2004). 
Under high stress conditions, apoptosis defi-
cient malignant cells may die by other mech-
anisms, improving the efficiency of some 
therapies (Gözüaçık and Kimchi, 2007; Yang 
et al., 2011). Lupeol also possesses anti-CRC 
potential, because modulates the Wnt/β-
catenin signaling pathway a hallmark from 
this pathology, this potential is displayed 
through inhibition of Wnt/β-catenin tran-
scriptional activity and decreasing the level 
of β-catenin in nuclei (Tarapore et al., 2013). 
Wnt/β-catenin pathway is one of the main 
critical control points for cell proliferation 
and cell polarity, thus promoting cell homeo-
stasis (MacDonald et al., 2009). All these ac-
tivities support the important biological po-
tential of lupane-type triterpenes in CRC 
management, and open the possibility that 
people take more awareness on plants natu-
rally occurring compounds as potential ther-
apeutic agents.  
 
Breast cancer 
Breast cancer is by now the second most 
common malignant tumor worldwide, the 
leading cause of cancer-related deaths in fe-
males, and the fifth of all cancer cases. This 
pathology had about 1.67 million of new 
cases (about 25 % of all cancers reported) 
and caused about 522,000 deaths in 2012. 
Breast cancer has the highest incidence rates 
in Western Europe and United States, while 
the lowest incidences occur in Asia and Af-
rica (Ferlay et al., 2014; Torre et al., 2015). 
Principal associated risk factors include be-
ing female, aging, genetic predisposition 
(BRCA1 and BRCA2 mutations), breast 
density, radiation exposure, nulliparity, long 
term hormonal therapy, and life style associ-
ated factors (obesity, sedentarism, etc.) 
(American Cancer Society, 2015b). The sur-
vival rate to this pathology has increased 
considerably in recent years, mostly due to 
prevention campaigns, self-exploration, and 
the development of more effective therapies. 
Survival rate has increased from 75 % in the 
70’s to 90 % in the first decade of 2000 
(Saadatmand et al., 2015). The five-year life 
expectancy is about 82.1 % (Arrington et al., 
2014). Breast cancer treatment is based on 
type of molecular markers expressed, such as 
estrogen receptor (ER), progesterone recep-
tor (PR) and HER2/neu. Principal treatments 
for this disease include surgery, radiotherapy 
chemotherapy, and hormonal therapy (Amer-
ican Cancer Society, 2015b). Lupeol, betulin 
and betulinic acid have shown good results 
against breast cancer in many conducted re-
searches. Methanolic extract from Nardosta-
chys jatamansi (lupeol rich plant) were test-
ed against ER+ cell line MCF-7 and ER- 
MDA-231, being more effective against 
MDA-231, promoting cell cycle arrest on 
G2/M phase and apoptosis induction 
(Chaudhary et al., 2015). This result is rele-
vant due to ER+ breast cancer tumors are 
hormone responsive, indicating that lupeol 
could exert effects on ER- tumors such as ba-
sal or triple negative, which are the most dif-
ficult mammary tumors to treat, because are 
unresponsive to typical hormone therapy. 
Another study demonstrated that lupeol iso-
lated from Elephantopus scaber, exerts its 
apoptotic activity through Bcl-2 and Bcl-xL 
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downregulation, leading to cytochrome c re-
lease and intrinsic apoptosis pathway induc-
tion. This effect was only seen on MCF-7 
(breast cancer), but not so on MCF-10A 
(normal cell line) (Pitchai et al., 2014).  
However, it is possible that the effect of lu-
peol against breast cancer is limited as re-
cently demonstrated, and that lupeol had no 
capability against invasive cells (Fu et al., 
2015). Betulin and betulinic acid are capable 
of selective apoptosis induction on invasive 
breast cancer cells, but not so in normal 
breast cells by upregulation of Bax, cleaved 
caspase-3, and cleaved PARP, increasing 
p53 and p21 levels and decreasing p-Akt 
(Hsu et al., 2015b). Betulinic acid-rich frac-
tion from Dillenia suffruticosa roots led to 
upregulation of p53, p21, and increasing the 
protein ratio of Bax to Blc-2 by 2, resulting 
on apoptosis induction (Foo et al., 2015). 
Betulinic acid also showed important effects 
on growth inhibition of ER- cells, which is a 
relevant finding since breast cancer ER- re-
lated tumors do have limited endocrine-
based therapies (Tzenov et al., 2015).  
 
CONCLUSIONS 
Interest for plant derived natural products 
as therapeutic agents has recently increased 
worldwide. Particularly, lupane-type triter-
penes such as betulin, betulinic acid and lu-
peol have shown multiple bioactivities 
against different cancer cell lines and hold 
encouraging antitumor effects. Their activity 
might be promising against lung, liver, stom-
ach, colorectal and breast cancers. Further 
research in vitro and in vivo, and human 
clinical trials are required to elucidate their 
mechanisms of action and their whole thera-
peutic potential. However, it exists great ex-
pectation for this class of compounds as 
therapeutic agents for combating malignant 
tumors. 
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